BookHadi Goubran, Gaafar Ragab, Suzy Hassouna, editors.
Contents:
Intro
Preface
Contents
Contributors
Chapter 1: Coagulation and Anticoagulants
Introduction
The Coagulation Cascade
Cell-Based Model of Hemostasis
Natural Anticoagulants, Predisposing Factors, and Exposing Factors of Clot Formation
Anticoagulants
Injectable Indirect Thrombin/Anti-Xa Inhibitors
Unfractionated Heparin (UFH)
Historic Background
Route and Dose
Therapeutic
Prophylactic
Side Effects
Contraindications
Reversal
Low-Molecular-Weight Heparins [LMWHs]
Indications and Dosage [39-46]
Warning and Precautions
Monitoring Pentasaccharide
Fondaparinux
Indication and Dose
Deep Vein Thrombosis Prophylaxis Following Hip Fracture, Hip Replacement, and Knee Replacement Surgery
Deep Vein Thrombosis Prophylaxis Following Abdominal Surgery
Deep Vein Thrombosis Prophylaxis in Medical Patients
Deep Vein Thrombosis and Pulmonary Embolism Treatment, Including HIT
Acute Coronary Syndrome
Warnings and Precautions
Vitamin K Antagonists [VKAs] and Warfarin
Warfarin
Historic Background
Bioavailability and Half-Life
Formulation
Dose and Administration
Warfarin Resistance Warfarin Interactions
Food, Food Supplement, and Herbal Interactions
Other Interactions
Drug Interactions [69-73]
Contraindications
Adverse Events
Injectable Direct Thrombin Inhibitors
Hirudins
Bivaluridin
Argatroban [103-106]
NOACs/DOACs
Contraindications
NOACs Include
Oral Direct Thrombin Inhibitor: Dabigatran
Indications
Dose
Contraindications [110]
Risk of Bleeding
Drug Interactions [110]
Other Drugs
Impact of Dabigatran on Other Drugs
Conversion to Warfarin [110]
Converting from or to Parenteral Anticoagulants Oral Direct Factor Xa Inhibitors
Apixaban [112]
Formulation
Indications
Contraindications [112]
Dose
Precautions in Special Populations [112]
Renal Impairment
Hepatic Impairment
Concomitant Use of Antiplatelet Agents
Drug Interactions [112]
Switching from to and from Other Anticoagulation Agents
Switching from or to Parenteral Anticoagulants
Switching from VKA to Apixaban
Switching from Apixaban to VKA
Anticoagulation Bridging (See Chap. 12)
Betrixaban [121]
Formulation
Indications
Dose
Precautions
Side Effects and Bleeding Risks Bleeding Reversal
Edoxaban [123]
Formulation
Indications
Contraindications [123, 126]
Precautions [123]
Drug Interactions: [120]
Switching Between Agents [123]
Bridging Anticoagulation (Please refer to Chap. 12)
Rivaroxaban [129]
Formulation
Indications
Dose
Precautions and Bleeding Risks
Switching from One Anticoagulant to Another
Switching from Parenteral Anticoagulants to Rivaroxaban
Switching from Rivaroxaban to Parenteral Anticoagulants
Switching from Vitamin K Antagonists (VKAs) to Rivaroxaban
Switching from Rivaroxaban to a VKA